Zoetis Inc. (NYSE: ZTS)
Drug Manufacturers - Specialty & Generic · Parsippany, NJ, United States · Founded 2013
- Market capitalization: $80.0 billion
- Annual revenue: $9.47 billion
- Net income: $2.67 billion
- Employees: 14,100
- Sector: Healthcare
- Headquarters: Parsippany, United States
- Founded: 2013
Source: Statvoo company profile for Zoetis Inc.. Browse all 500+ companies
Zoetis is the world's largest animal health company, developing and manufacturing medicines, vaccines, and diagnostic products for livestock and companion animals. Spun off from Pfizer in 2013, Zoetis serves veterinarians, livestock producers, and pet owners in over 100 countries. The company's blockbuster products include Simparica (parasiticides), Apoquel (dermatology), and Librela (pain management).
Zoetis earns revenue from the sale of animal health pharmaceuticals, vaccines, and diagnostics. The companion animal segment has become the primary growth driver, benefiting from increasing pet ownership and willingness to spend on pet healthcare.
Zoetis was Pfizer's animal health division before being spun off in a 2013 IPO that raised $2.2 billion. The company has invested heavily in monoclonal antibody technology for animals, launching Librela for dogs and Solensia for cats—the first monoclonal antibody treatments approved for companion animals. These products have become some of the fastest-growing in animal health history.
| Market Capitalization | $80.0B |
| Annual Revenue | $9.47B |
| Net Income | $2.67B |
| Profit Margin | 28% |
| Revenue per Employee | $671631K |
| Stock Exchange | NYSE |
| Ticker Symbol | ZTS |
Financial data is approximate and based on most recent annual filings.
Librela, Zoetis's pain treatment for dogs, reached $500 million in revenue faster than almost any animal health product in history. The company vaccinates more animals annually than any other organization in the world.
Zoetis is the Pfizer of animal health—dominant, innovative, and riding the secular trend of pet humanization. Librela and Solensia are franchise-defining products that could generate billions in peak sales, and the pipeline behind them is deep.
What is Zoetis Inc.'s revenue?
Zoetis Inc. generates approximately $9.47 billion in annual revenue.
How many employees does Zoetis Inc. have?
Zoetis Inc. employs approximately 14,100 people worldwide.
What is Zoetis Inc.'s market cap?
Zoetis Inc. (ZTS) has a market capitalization of approximately $80.0 billion on the NYSE.
When was Zoetis Inc. founded?
Zoetis Inc. was founded in 2013 and is headquartered in Parsippany, NJ, United States.
Who is the CEO of Zoetis Inc.?
Kristin Peck is the current CEO of Zoetis Inc..
What is Zoetis Inc.'s website?
Zoetis Inc.'s official website is zoetis.com.
| CEO | Kristin Peck |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Founded | 2013 |
| HQ | Parsippany, NJ |
| Country | United States |
| Website | zoetis.com |
See traffic, security, and technical data for Zoetis Inc.'s website:
📊 zoetis.com stats 📋 WHOIS 🌐 DNS 🔒 SSL